Go or no go? The FDA’s Amylyx dilemma
June will see adcoms aplenty, with Bluebird, Acadia, and the Covid vaccine makers Novavax, Pfizer/Biontech and Moderna all facing FDA committees.
The patent winter is coming
Biopharma is approaching the most painful period of patent loss for at least 30 years. Is M&A an answer?
Despite slow progress, Boehringer keeps faith in oncology
The group highlights its ambitions in cancer again, but is at least two years away from launching a new product.
Go or no go? Bristol’s Lag3 debut
March Pdufa dates are set for relatlimab as well as Akebia’s vadadustat, while Amylyx’s ALS drug heads for a panel.
